for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion



A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas


Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational, single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of enrollment into cohorts where treatment appears futile, and will include the following cohorts of patients with EBV+ relapsed/refractory lymphomas:

  1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS)
  2. Extranodal NK/T-cell lymphoma (ENKTL)
  3. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL
  4. Hodgkin lymphoma (HL)
  5. Post-transplant lymphoproliferative disorder (PTLD)
  6. HIV-associated lymphomas (Plasmablastic, Burkitt, Hodgkin, DLBCL)
  7. EBV+ lymphoproliferative disorders other than the above


Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, Extranodal NK/T-cell Lymphoma, EBV-Positive DLBCL, Nos, EBV Associated Lymphoma, EBV-Related Hodgkin Lymphoma, EBV Related PTCL, Nos, EBV positive post-transplant lymphoproliferative disorder (PTLD), EBV lymphoma, HIV-associated lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus (EBV), EBV positive T cell lymphoma, Epstein-Barr Virus Infections, Lymphoma, T-Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Extranodal NK-T-Cell Lymphoma, Valganciclovir, Nanatinostat in combination with valganciclovir


You can join if…

Open to people ages 18 years and up

  • EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies
  • EBV+ DLBCL, NOS: Must have received at least one course of an anti-CD20 immunotherapy, and at least one course of anthracycline-based chemotherapy
  • PTLD: Must have received immunotherapy with an anti-CD20 agent.
  • Hodgkin lymphoma: Must have received at least one course of anthracycline-based chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be ineligible for an anti-PD-1 agent and CD30-directed therapy.
  • For ENKTL and PTCL patients only: Relapsed/refractory disease following 1 or more prior systemic therapies. ENKTL patients must have failed an asparaginase-containing regimen.
  • No available therapies in the opinion of the Investigator
  • Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy
  • Measurable disease per Lugano 2007
  • ECOG performance status 0, 1, 2
  • Adequate bone marrow function

You CAN'T join if...

  • Presence or history of CNS involvement by lymphoma
  • Systemic anticancer therapy or CAR-T within 21 days
  • Antibody (anticancer) agents within 28 days
  • Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant
  • Less than 90 days from prior allogeneic transplant.
  • Daily corticosteroids (≥20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1
  • Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir.
  • Active infection requiring systemic therapy (excluding viral upper respiratory tract infections).


  • UCSF Hematology and Blood and Marrow Transplant accepting new patients
    San Francisco California 94143 United States
  • The Oncology Institute of Hope and Innovation accepting new patients
    Torrance California 90503 United States


accepting new patients
Start Date
Completion Date
Viracta Therapeutics, Inc.
Phase 2 research study
Study Type
Expecting 140 study participants
Last Updated